NEUROSENSE THERAPEUTICS LTD (NRSN)
IL0011809592 - Common Stock
We assign a fundamental rating of 0 out of 10 to NRSN. NRSN was compared to 564 industry peers in the Biotechnology industry. NRSN has a bad profitability rating. Also its financial health evaluation is rather negative. NRSN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year NRSN has reported negative net income.
NRSN had a negative operating cash flow in the past year.
In the past 5 years NRSN always reported negative net income.
NRSN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of NRSN (-407.98%) is worse than 96.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -407.98% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-170.91%
ROA(5y)-200.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NRSN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NRSN has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, NRSN has an improved debt to assets ratio.
2.2 Solvency
NRSN has an Altman-Z score of -40.48. This is a bad value and indicates that NRSN is not financially healthy and even has some risk of bankruptcy.
NRSN's Altman-Z score of -40.48 is on the low side compared to the rest of the industry. NRSN is outperformed by 93.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -40.48 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.46 indicates that NRSN may have some problems paying its short term obligations.
NRSN has a worse Current ratio (0.46) than 93.58% of its industry peers.
A Quick Ratio of 0.46 indicates that NRSN may have some problems paying its short term obligations.
The Quick ratio of NRSN (0.46) is worse than 93.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.46 | ||
| Quick Ratio | 0.46 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 27.17% over the past year.
EPS 1Y (TTM)27.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-244.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, NRSN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.95% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.71%
EPS Next 2Y16.06%
EPS Next 3Y15.95%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NRSN. In the last year negative earnings were reported.
Also next year NRSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NRSN's earnings are expected to grow with 15.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.06%
EPS Next 3Y15.95%
5. Dividend
5.1 Amount
NRSN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEUROSENSE THERAPEUTICS LTD
NASDAQ:NRSN (12/30/2024, 12:38:44 PM)
1.21
-0.07 (-5.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners8.58%
Inst Owner ChangeN/A
Ins Owners25.43%
Ins Owner ChangeN/A
Market Cap27.99M
Analysts82.5
Price Target7.65 (532.23%)
Short Float %2.06%
Short Ratio1.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.41%
Min EPS beat(2)-67.38%
Max EPS beat(2)90.2%
EPS beat(4)3
Avg EPS beat(4)46.1%
Min EPS beat(4)-67.38%
Max EPS beat(4)140.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)42.86%
PT rev (3m)42.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.57%
EPS NY rev (1m)0%
EPS NY rev (3m)19.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS-0.07
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -407.98% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-170.91%
ROA(5y)-200.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 3.45% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.46 | ||
| Quick Ratio | 0.46 | ||
| Altman-Z | -40.48 |
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-244.71%
EPS Next Y14.71%
EPS Next 2Y16.06%
EPS Next 3Y15.95%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-84.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.41%
OCF growth 3YN/A
OCF growth 5YN/A